SynthesisJMIR public health and surveillance2025
Minimum Data Set and Metadata for Active Vaccine Safety Surveillance: Systematic Review.
Synthesis in JMIR public health and surveillance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Active vaccine safety surveillance (AVSS) stands as a top priority for the World Health Organization (WHO), serving as a critical indicator of the fourth maturity level for national regulatory agencies. Objective: This review aims to define the minimal data scope for association studies in vaccine safety, providing a reference framework for implementing AVSS systems worldwide, especially in low- and middle-income countries. Methods: The study systematically searched PubMed, Embase, and Web of Science for cohort and case-control studies related to AVSS published between January 1, 2018, and September 7, 2022. Guided by the WHO and Council for International Organizations of Medical Sciences guidelines (CIOMS), we developed a 4D framework for Minimum Data Sets (MDSs), including "Vaccine," "Outcome," "Demographic Data," and "Covariate." Variables with a frequency of at least 5% were included in the MDS. Results: Of the 123 included studies, 102 (82.9%) were cohort studies and 98 (79.7%) originated from high-income countries, covering populations across the entire life course. The MDS for COVID-19 vaccines identified 54 variables, while the MDS for maternal populations included 96 variables. WHO guidelines were found to align better with practical applications compared to CIOMS guidelines, though both require further optimization based on the MDS findings. However, metadata for these essential variables were inadequately described across the studies. Conclusions: The proposed MDS provides clear guidance and concise requirements for AVSS data scope. Establishing a globally standardized MDS and comprehensive metadata based on these findings is essential to enhancing the global vaccine safety ecosystem.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.